Monday, 20 May 2019

Taiwan recognizes Parexel as best CRO

02 July 2014 | News | By BioSpectrum Bureau

Parexel has a strong presence to support both international, multi-center trials that include APAC as well as region and country-specific needs

Parexel has a strong presence to support both international, multi-center trials that include APAC as well as region and country-specific needs

Singapore: Foundation of Medical Professionals Alliance in Taiwan (FMPAT) has recognized contract research firm, PAREXEL, as the 2014 Best Performing CRO in Taiwan.

"Parexel applies its scientific expertise and innovative approaches to reducing clinical trial complexity to help create greater opportunities for clinical research in Taiwan and across the region," said Mr Albert Liou, vice chairman-asia pacific, Taiwan. "We appreciate this recognition of our ongoing commitment to simplifying drug development for our customers and supporting their efforts to prevent and cure disease."

Two years ago, Parexel formed an alliance with National Taiwan University Hospital to strengthen its ability to meet customer demand for end-to-end services in Taiwan.

"Parexel has a strong presence to support both international, multi-center trials that include APAC as well as region and country-specific needs," said Mr Mark A Goldberg, president and chief operating officer, Parexel. "With 4,400 employees in 23 locations across 12 countries in the region, PAREXEL offers an unparalleled infrastructure to support customers across the entire development continuum."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls